Case Series of Dermatologic Events Associated With the Insulin-Like Growth Factor Receptor 1 Inhibitor Cixutumumab

Similar Items

• Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
  od: Lacouture, Mario E., i dr.
  Izdano: (2020)
• A Phase II Study of Cixutumumab (IMC-A12, NSC742460) in Advanced Hepatocellular Carcinoma
  od: Abou-Alfa, Ghassan K., i dr.
  Izdano: (2013)
• Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
  od: Lacouture, Mario E., i dr.
  Izdano: (2020)
• Dermatological adverse events with taxane chemotherapy
  od: Sibaud, Vincent, i dr.
  Izdano: (2016)
• Dermatologic Adverse Events Associated with use of Adjuvant Lapatinib in Combination with Paclitaxel and Trastuzumab for HER2 positive Breast Cancer: A Case Series Analysis
  od: Friedman, Marissa D., i dr.
  Izdano: (2015)